• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UMass Dartmouth MAB to house biomanufacturing startups

UMass Dartmouth MAB to house biomanufacturing startups

May 18, 2012
CenterWatch Staff

The University of Massachusetts Dartmouth has broken ground on the site for their new Massachusetts Accelerator for Biomanufacturing (MAB), a facility for startup companies to test biomanufacturing methods and bioproducts located in Fall River, Mass.

"Massachusetts is leading the world in the life sciences thanks to our growth strategy of investing in education, innovation and infrastructure," said Massachusetts governor Deal Patrick. "I am proud of this investment and I look forward to seeing the Massachusetts Accelerator for Biomanufacturing create jobs and further strengthen our leadership in the life sciences."

On completion next fall, the MAB will be the only facility in the U.S. where startups will be able to test their biomanufacturing methods and bioproducts at every stage of development and access full-service support from business and marketing to pure science support.

"I welcome this new facility as a sign of UMass Dartmouth's emergence as a major research enterprise within the University of Massachusetts," said UMass president Robert L. Caret. "Currently, UMass is number one in life sciences patents among universities in Massachusetts and number two in New England for royalties from products we've commercialized. The MAB will build on the strengths of the UMass system, and take UMass Dartmouth to the next level in research."

Construction of the $28 million facility will create approximately 120 jobs, and 10 UMass Dartmouth employees will serve on staff. As the anchor tenant of the SouthCoast Life Science and Technology Park, the MAB is expected to leverage the creation of as many as 8,000 jobs once the Park is operating at full capacity. Because the MAB is being built to cGMP-like standards, it will offer high quality at a lower cost—meaning greater flexibility and faster turnaround times to prove products and bring them to market.

The MAB is designed to serve researchers and entrepreneurs as they scale up products and methods that will reshape the fields of biotherapeutics, biomedicine and green chemistry. The 35,000 sq. ft. facility will house four production suites, quality control labs, an R&D suite, training lab, lecture halls, office suite and presentation/public access area. Here, industry pioneers will grow antibodies to fight disease, generate new tissue from stem cells, create a new generation of biofuels and more. The MAB will also offer unique services to clients through the MAB Network, a web of preferred partners across the region and the state. Members of the network will assay and validate products and make seamless, cost-effective transitions to full-scale production a reality.

The Commonwealth invested $14.6 million in the project through a capital grant from the Massachusetts Life Science Center. UMass Dartmouth is investing $10 million in capital funds and another $3 million is anticipated from equipment grants and corporate donations. In addition, the Commonwealth invested $38 million of ARRA funds to construct a new exit ramp from Route 24 that provides direct highway access to the 300-acre "Biopark" in Fall River—the largest ARRA-funded public works project in the Commonwealth.

"The UMass building authority is thrilled to bring projects like this one to reality that not only benefit the university and its students, but also add to the economic development of the region," said Katherine Craven, executive director, UMass building authority. "Our goal is to build a world-class facility unlike any other in the country that will keep entrepreneurs in the area and attract new life-science start-ups to Massachusetts."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing